How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

198,798 results for

Risk Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

198361. Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients

Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Clinical and Economic Benefits of Cardiovascular Risk Management by a Dietician in Type 2 Diabetes Patients (GRC) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00444899 Recruitment Status : Active, not recruiting First Posted : March 8

2007 Clinical Trials

198362. Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk

Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00523536 Recruitment Status : Completed First Posted : August

2007 Clinical Trials

198363. Multifactor Risk Reduction for Optimal Management of PAD

Multifactor Risk Reduction for Optimal Management of PAD Multifactor Risk Reduction for Optimal Management of PAD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Multifactor Risk Reduction for Optimal (...) for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 300 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Home-based exercise Masking: Single (Participant) Primary Purpose: Treatment Official Title: Multifactor Risk Reduction for Optimal Management of PAD Study Start Date : September 2006 Estimated Primary Completion Date : June 2018 Estimated Study Completion Date : June 2018 Resource links provided

2007 Clinical Trials

198364. Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)

Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038) Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00139438 Recruitment Status : Completed First Posted : August 31, 2005 Last Update Posted : April 22, 2016 Sponsor: Merck Sharp & Dohme Corp. Information

2005 Clinical Trials

198365. Telephone Disease Management At-Risk Drinking (TDM II)

Telephone Disease Management At-Risk Drinking (TDM II) Telephone Disease Management At-Risk Drinking (TDM II) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Telephone Disease Management At-Risk Drinking (...) of Research and Development ( US Department of Veterans Affairs ) Study Details Study Description Go to Brief Summary: The aim of this study is to test for improvements in treatment outcomes for primary care patients with at-risk drinking when cared for using telephone disease management (TDM) compared to those treated with usual care. Based on our pilot data, TDM for at-risk drinking may be a viable method for reducing alcohol consumption in this population. Hypotheses: The hypotheses for this research

2005 Clinical Trials

198366. Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel)

Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel) Diabetes Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Diabetes (...) Risk Evaluation and Management Tele-monitoring Study (DREAM-Tel) (DREAM-Tel) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00325624 Recruitment Status : Completed First Posted : May 15, 2006 Last Update Posted : May 23, 2012 Sponsor: Sunnybrook Health Sciences Centre Collaborators: Battlefords

2006 Clinical Trials

198367. Reducing risks in diabetes self-management: a systematic review of the literature. (PubMed)

Reducing risks in diabetes self-management: a systematic review of the literature. The purpose of this systematic review was to review published literature on risk-reducing interventions as part of diabetes self-management.Medline (1990-2007), CINAHL (1990-2007), and Cochrane Central Register of Controlled Trials (first quarter 2007) databases were searched. Reference lists from included studies were reviewed to identify additional studies.Intervention studies that addressed reducing risks (...) were significantly improved.Reducing risks involves implementing effective risk reduction behaviors to prevent or slow the progression of diabetes complications. Recognizing risk factors for complications and what constitutes optimal preventive care is an important part of managing diabetes. Intervention studies are lacking in some areas of reducing risks. Further studies are needed to test specific interventions to reduce the risks of diabetes complications.

2007 The Diabetes educator

198368. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. (PubMed)

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum

2006 Expert opinion on investigational drugs

198369. Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome. (PubMed)

Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome. Routine use of an invasive strategy (IS) has been shown to exceed a conservative strategy in reducing myocardial infarction (MI), angina and re-hospitalization rate in patients with non-ST elevation acute coronary syndrome (NSTEACS). The present study aimed to analyse, by use of randomized trials data, whether the risk profile of patients with NSTEACS (...) = 0.001, P heterogeneity = 0.07).The main finding of this meta-analysis is that, compared to a conservative strategy, the benefits of IS for the management of NSTEACS in terms of death/MI reduction are related to the patient's risk profile.

2007 Journal of cardiovascular medicine (Hagerstown, Md.)

198370. Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: benefits and risks. (PubMed)

Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: benefits and risks. BACKGROUND; Cyclo-oxygenase-2 inhibitors (COX-2i) demonstrate analgesic efficacy for patients who require gastrointestinal safety. The authors discuss the potential benefits and risks of these novel, but expensive, analgesics when used in dentistry.The authors conducted a MEDLINE search focused on the subject headings of common analgesic drugs and COX-2i, using peer-reviewed journals

2005 Journal of the American Dental Association

198371. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. (PubMed)

Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Cancer patients often receive transfusions when their hemoglobin concentration falls to dangerously low levels due to chemotherapy or due to the disease itself. The availability of recombinant human erythropoietin (rHuEPO) has significantly reduced transfusion frequencies in cancer patients. However, the predictability of transfusions (...) prior to the use of rHuEPO for future transfusions has not been evaluated. Data from five randomized, double-blind, placebo-controlled trials in cancer patients receiving chemotherapy and epoetin alfa were utilized to calculate the relative risk of subsequent transfusions in patients who were pretransfused. A meta-analysis with patient-level data was used to assess predictors of transfusion. Baseline data from an open-label study were used to compare quality-of-life (QOL) parameters between

Full Text available with Trip Pro

2005 The oncologist

198372. Active management of risk in pregnancy at term in an urban population: an association between a higher induction of labor rate and a lower cesarean delivery rate. (PubMed)

Active management of risk in pregnancy at term in an urban population: an association between a higher induction of labor rate and a lower cesarean delivery rate. The purpose of this study was to determine whether exposure to an alternative method of care, called the active management of risk in pregnancy at term, was associated with a lower group cesarean delivery rate.Active management of risk in pregnancy at term used risk factors for cesarean delivery to guide an increased use of labor (...) induction. A retrospective cohort design was used to compare clinical outcomes of 100 pregnant women who were exposed to active management of risk in pregnancy at term to 300 randomly selected subjects who received standard management.The 2 groups had comparable levels of prenatal risk. The group exposed to the active management of risk in pregnancy at term exposure group encountered a higher induction rate (63% vs 25.7%; P < .001) and a lower cesarean delivery rate (4% vs 16.7%; P = .01). Findings were

2004 American journal of obstetrics and gynecology

198373. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. (PubMed)

Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. The aim of this study was to determine whether multidisciplinary strategies improve outcomes for heart failure (HF) patients.Because the prognosis of HF remains poor despite pharmacotherapy, there is increasing interest in alternative models of care delivery for these patients.Randomized trials of multidisciplinary management programs in HF were (...) identified by searching electronic databases and bibliographies and via contact with experts.Twenty-nine trials (5,039 patients) were identified but were not pooled, because of considerable heterogeneity. A priori, we divided the interventions into homogeneous groups that were suitable for pooling. Strategies that incorporated follow-up by a specialized multidisciplinary team (either in a clinic or a non-clinic setting) reduced mortality (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.59 to 0.96

Full Text available with Trip Pro

2004 Journal of the American College of Cardiology

198374. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. (PubMed)

Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Patients with chronic kidney disease (CKD) have a high burden of mortality and cardiovascular morbidity. Additional strategies to modulate cardiovascular risk in this population are needed. Data suggest that anemia is a potent and potentially modifiable risk factor for cardiovascular disease in patients with CKD, but these data (...) Hb is again Hb > or =9 g/dL. TREAT is event-driven and has a composite primary end point comprising time to mortality and nonfatal cardiovascular events, including myocardial infarction, myocardial ischemia, stroke, and heart failure. TREAT will provide data that are critical to evolution of the management of cardiovascular risk in this high-risk population.

2005 American heart journal

198375. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. (PubMed)

Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. In patients with non-ST-elevation acute coronary syndromes (NSTE ACS), enoxaparin has been shown to be superior to unfractionated heparin (UFH) and is associated with a reduction in ischemic end points with nonsignificant increases in bleeding. However, the critical trials comparing enoxaparin with UFH were conducted before the widespread use of early (...) invasive management and the availability of clopidogrel and glycoprotein IIb/IIIa receptor antagonists.SYNERGY was an international, multicenter, randomized, open-label trial that compared enoxaparin with UFH in high-risk NSTE ACS patients managed with an early invasive strategy. For enrollment, 2 out of 3 high-risk features were required: age > or =60 years, elevated cardiac biomarkers, or ST-segment changes. The primary efficacy end point was death/myocardial infarction (MI) at 30 days. The primary

2005 American heart journal

198376. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. (PubMed)

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Men with prostate cancer may live as long as men their age without prostate cancer. Those with low-risk disease may benefit from expectant management, which actively monitors disease progression. Dutasteride, a dual 5alpha-reductase inhibitor (5ARI), may delay prostate cancer progression or extend the time to initiation (...) of more aggressive therapy.The Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial will evaluate whether dutasteride decreases time to prostate cancer progression. Three hundred candidates for expectant management with biopsy-proven, low-risk, localized prostate cancer will receive dutasteride 0.5 mg/day or placebo for 3 years. Eligible men are between 50 and 80 years of age, have clinical stage T1c-T2a prostate cancer, a Gleason score of less than or equal

2007 Contemporary clinical trials

198377. The impact of cardiovascular risk factor case management on the metabolic syndrome in a primary prevention population: results from a randomized controlled trial. (PubMed)

The impact of cardiovascular risk factor case management on the metabolic syndrome in a primary prevention population: results from a randomized controlled trial. No study has examined the effect of case management on the development of the metabolic syndrome. The authors randomized 450 consenting, asymptomatic men and women to a 6-month cardiovascular case management program or usual care. Participants were reassessed at 1 year for change in a composite measure of five factors that define (...) the metabolic syndrome. Of the cohort (mean age 42 years; 79% male), 46% had at least one metabolic syndrome factor and 4.3% had the metabolic syndrome. At 1 year, there was greater improvement in motivation to change in the case management group (+0.58 vs. +0.06, 10-point scale; p = 0.001), lower incidence of the metabolic syndrome (1.5% vs. 4.5%; p = 0.12), and lower prevalence (decrease of 0.8% vs. increase of 2.6%; p = 0.04). A 6-month case management program focused on cardiovascular risk factors had

2006 Journal of the cardiometabolic syndrome

198378. Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery

Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00479011 Recruitment Status : Terminated (significant reduction in length of hospital stay (primary

2007 Clinical Trials

198379. A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care

A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. A Study on Improving Detection and Management of Suicide Risk Among Depressed Patients in Primary Care The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00386711 Recruitment Status : Unknown Verified October 2006 by Nanjing Medical University. Recruitment

2006 Clinical Trials

198380. Adapting Tools to Implement Stroke Risk Management to Veterans

Adapting Tools to Implement Stroke Risk Management to Veterans Adapting Tools to Implement Stroke Risk Management to Veterans - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adapting Tools to Implement (...) Stroke Risk Management to Veterans (TOOLS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00355147 Recruitment Status : Completed First Posted : July 21, 2006 Results First Posted : February 10, 2015 Last Update Posted : October 11, 2018 Sponsor: VA Office of Research and Development Collaborator

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>